TSE:PLI - ProMetic Life Sciences Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started C$0.78 +0.01 (+1.30 %) (As of 07/23/2018 01:58 AM ET)Previous CloseC$0.78Today's RangeC$0.74 - C$0.7852-Week RangeC$0.45 - C$1.80Volume704,600 shsAverage Volume1.44 million shsMarket CapitalizationC$1.04 billionP/E RatioN/ADividend YieldN/ABeta2.59 Company ProfileAnalyst RatingsEarnings HistoryInsider TradesHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies. The Small-Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, chronic kidney diseases/diabetic kidney diseases, and metabolic syndrome and its resulting type 2 diabetes, cystic fibrosis related diabetes and liver steatosis, and Alström syndrome. The Plasma-Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. The Bioseparation Technologies segment develops and commercializes affinity chromatography products related to the bioseparation, pathogen reduction, and protein purification. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada. Receive PLI News and Ratings via Email Sign-up to receive the latest news and ratings for PLI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolTSE:PLI CUSIPN/A Webprometic.com Phone+1-450-7810115 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-73.85% Return on Equity-48.83% Return on Assets-26.09% Miscellaneous EmployeesN/A Outstanding Shares712,330,000Market CapC$1,040.00 ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions What is ProMetic Life Sciences' stock symbol? ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI." How were ProMetic Life Sciences' earnings last quarter? ProMetic Life Sciences Inc. (TSE:PLI) posted its earnings results on Tuesday, May, 15th. The company reported ($0.04) earnings per share for the quarter. The firm had revenue of $4.29 million for the quarter. ProMetic Life Sciences had a negative net margin of 73.85% and a negative return on equity of 48.83%. View ProMetic Life Sciences' Earnings History. When is ProMetic Life Sciences' next earnings date? ProMetic Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for ProMetic Life Sciences. What price target have analysts set for PLI? 4 brokers have issued twelve-month price objectives for ProMetic Life Sciences' stock. Their predictions range from C$0.60 to C$2.00. On average, they anticipate ProMetic Life Sciences' stock price to reach C$1.47 in the next twelve months. This suggests a possible upside of 88.5% from the stock's current price. View Analyst Ratings for ProMetic Life Sciences. What is the consensus analysts' recommendation for ProMetic Life Sciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of ProMetic Life Sciences' key competitors? Some companies that are related to ProMetic Life Sciences include ABLYNX NV/ADR (ABLX), MorphoSys (MPSYY), BTG (BTG), Abcam (ABC), MorphoSys (MOR), Almirall (LBTSF), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF) and Emerald Health Therapeutics (EMH). Who are ProMetic Life Sciences' key executives? ProMetic Life Sciences' management team includes the folowing people: Mr. Pierre Laurin, Pres, CEO & Non-Independent Director (Age 57)Mr. Bruce Pritchard, COO & Interim CFOMr. Patrick Sartore, Chief Legal Officer & Corp. Sec.Mr. Bruce Wendel, Chief Bus. Devel. Officer & Director (Age 64)Dr. John Moran, Chief Medical Officer (Age 72) Has ProMetic Life Sciences been receiving favorable news coverage? News stories about PLI stock have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ProMetic Life Sciences earned a coverage optimism score of 0.12 on Accern's scale. They also assigned media stories about the company an impact score of 45.54 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. How do I buy shares of ProMetic Life Sciences? Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is ProMetic Life Sciences' stock price today? One share of PLI stock can currently be purchased for approximately C$0.78. How big of a company is ProMetic Life Sciences? ProMetic Life Sciences has a market capitalization of C$1.04 billion. How can I contact ProMetic Life Sciences? ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115. MarketBeat Community Rating for ProMetic Life Sciences (TSE PLI)Community Ranking: 3.5 out of 5 ( )Outperform Votes: 326 (Vote Outperform)Underperform Votes: 137 (Vote Underperform)Total Votes: 463MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?